Assessing Cardiovascular Target Attainment in Type 2 Diabetes Mellitus Patients in Tertiary Diabetes Center in Romania

Introduction: Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) share a bidirectional link, and the innovative antidiabetic molecules GLP-1 Ras and SGLT-2is have proven cardiac and renal benefits, respectively. This study aimed to evaluate CV risk categories, along with lipid-lowering...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Pharmaceuticals (Basel, Switzerland) Ročník 17; číslo 9; s. 1249
Hlavní autori:	Salmen, Teodor, Pietrosel, Valeria-Anca, Reurean-Pintilei, Delia, Iancu, Mihaela Adela, Cimpeanu, Radu Cristian, Bica, Ioana-Cristina, Dumitriu-Stan, Roxana-Ioana, Potcovaru, Claudia-Gabriela, Salmen, Bianca-Margareta, Diaconu, Camelia-Cristina, Cretoiu, Sanda Maria, Stoian, Anca Pantea
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Switzerland MDPI AG 01.09.2024 MDPI
Predmet:	Antidiabetics Atherosclerosis cardio-renal protection cardiovascular disease Cardiovascular diseases Care and treatment Complications and side effects Demographic aspects Diabetes Diabetic neuropathy Diagnosis Disease Exercise Fatalities Glucose LDL-cholesterol Lipids Metabolic disorders Mortality Oxidative stress Patients risk Risk factors statin Statins Type 2 diabetes type 2 diabetes mellitus Weight control Romania LDL-cholesterol cardiovascular disease statin type 2 diabetes mellitus risk cardio-renal protection sodium-glucose co-transporter-2 inhibitors glucagon-like peptide-1 receptor agonists
ISSN:	1424-8247, 1424-8247
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Introduction: Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) share a bidirectional link, and the innovative antidiabetic molecules GLP-1 Ras and SGLT-2is have proven cardiac and renal benefits, respectively. This study aimed to evaluate CV risk categories, along with lipid-lowering and antidiabetic treatments, in patients with T2DM from a real-life setting in Romania. Material and Methods: A cross-sectional evaluation was conducted on 405 consecutively admitted patients with T2DM in an ambulatory setting, assessing them according to the 2019 ESC/EAS guidelines for moderate, high, and very high CV risk categories. Results: The average age of the group was 58 ± 9.96 years, with 38.5% being female. The mean HbA1C level was 7.2 ± 1.7%. Comorbidities included HBP in 88.1% of patients, with a mean SBP and DBP of 133.2 ± 13.7 mm Hg and 79.9 ± 9 mm Hg, respectively, and obesity in 66.41%, with a mean BMI of 33 ± 6.33 kg/m2. The mean LDL-C levels varied by CV risk category: 90.1 ± 34.22 mg/dL in very high risk, 98.63 ± 33.26 mg/dL in high risk, and 105 ± 37.1 mg/dL in moderate risk. Prescribed treatments included metformin (100%), statins (77.5%), GLP-1 Ras (29.4%), and SGLT-2is (29.4%). Conclusions: In Romania, patients with T2DM often achieve glycemic control targets but fail to meet composite targets that include glycemic, BP, and lipid control. Additionally, few patients benefit from innovative glucose-lowering therapies with proven cardio-renal benefits or from statins.
AbstractList	Introduction: Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) share a bidirectional link, and the innovative antidiabetic molecules GLP-1 Ras and SGLT-2is have proven cardiac and renal benefits, respectively. This study aimed to evaluate CV risk categories, along with lipid-lowering and antidiabetic treatments, in patients with T2DM from a real-life setting in Romania. Material and Methods: A cross-sectional evaluation was conducted on 405 consecutively admitted patients with T2DM in an ambulatory setting, assessing them according to the 2019 ESC/EAS guidelines for moderate, high, and very high CV risk categories. Results: The average age of the group was 58 ± 9.96 years, with 38.5% being female. The mean HbA1C level was 7.2 ± 1.7%. Comorbidities included HBP in 88.1% of patients, with a mean SBP and DBP of 133.2 ± 13.7 mm Hg and 79.9 ± 9 mm Hg, respectively, and obesity in 66.41%, with a mean BMI of 33 ± 6.33 kg/m[sup.2] . The mean LDL-C levels varied by CV risk category: 90.1 ± 34.22 mg/dL in very high risk, 98.63 ± 33.26 mg/dL in high risk, and 105 ± 37.1 mg/dL in moderate risk. Prescribed treatments included metformin (100%), statins (77.5%), GLP-1 Ras (29.4%), and SGLT-2is (29.4%). Conclusions: In Romania, patients with T2DM often achieve glycemic control targets but fail to meet composite targets that include glycemic, BP, and lipid control. Additionally, few patients benefit from innovative glucose-lowering therapies with proven cardio-renal benefits or from statins. Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) share a bidirectional link, and the innovative antidiabetic molecules GLP-1 Ras and SGLT-2is have proven cardiac and renal benefits, respectively. This study aimed to evaluate CV risk categories, along with lipid-lowering and antidiabetic treatments, in patients with T2DM from a real-life setting in Romania.INTRODUCTIONType 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) share a bidirectional link, and the innovative antidiabetic molecules GLP-1 Ras and SGLT-2is have proven cardiac and renal benefits, respectively. This study aimed to evaluate CV risk categories, along with lipid-lowering and antidiabetic treatments, in patients with T2DM from a real-life setting in Romania.A cross-sectional evaluation was conducted on 405 consecutively admitted patients with T2DM in an ambulatory setting, assessing them according to the 2019 ESC/EAS guidelines for moderate, high, and very high CV risk categories.MATERIAL AND METHODSA cross-sectional evaluation was conducted on 405 consecutively admitted patients with T2DM in an ambulatory setting, assessing them according to the 2019 ESC/EAS guidelines for moderate, high, and very high CV risk categories.The average age of the group was 58 ± 9.96 years, with 38.5% being female. The mean HbA1C level was 7.2 ± 1.7%. Comorbidities included HBP in 88.1% of patients, with a mean SBP and DBP of 133.2 ± 13.7 mm Hg and 79.9 ± 9 mm Hg, respectively, and obesity in 66.41%, with a mean BMI of 33 ± 6.33 kg/m2. The mean LDL-C levels varied by CV risk category: 90.1 ± 34.22 mg/dL in very high risk, 98.63 ± 33.26 mg/dL in high risk, and 105 ± 37.1 mg/dL in moderate risk. Prescribed treatments included metformin (100%), statins (77.5%), GLP-1 Ras (29.4%), and SGLT-2is (29.4%).RESULTSThe average age of the group was 58 ± 9.96 years, with 38.5% being female. The mean HbA1C level was 7.2 ± 1.7%. Comorbidities included HBP in 88.1% of patients, with a mean SBP and DBP of 133.2 ± 13.7 mm Hg and 79.9 ± 9 mm Hg, respectively, and obesity in 66.41%, with a mean BMI of 33 ± 6.33 kg/m2. The mean LDL-C levels varied by CV risk category: 90.1 ± 34.22 mg/dL in very high risk, 98.63 ± 33.26 mg/dL in high risk, and 105 ± 37.1 mg/dL in moderate risk. Prescribed treatments included metformin (100%), statins (77.5%), GLP-1 Ras (29.4%), and SGLT-2is (29.4%).In Romania, patients with T2DM often achieve glycemic control targets but fail to meet composite targets that include glycemic, BP, and lipid control. Additionally, few patients benefit from innovative glucose-lowering therapies with proven cardio-renal benefits or from statins.CONCLUSIONSIn Romania, patients with T2DM often achieve glycemic control targets but fail to meet composite targets that include glycemic, BP, and lipid control. Additionally, few patients benefit from innovative glucose-lowering therapies with proven cardio-renal benefits or from statins. Introduction: Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) share a bidirectional link, and the innovative antidiabetic molecules GLP-1 Ras and SGLT-2is have proven cardiac and renal benefits, respectively. This study aimed to evaluate CV risk categories, along with lipid-lowering and antidiabetic treatments, in patients with T2DM from a real-life setting in Romania. Material and Methods: A cross-sectional evaluation was conducted on 405 consecutively admitted patients with T2DM in an ambulatory setting, assessing them according to the 2019 ESC/EAS guidelines for moderate, high, and very high CV risk categories. Results: The average age of the group was 58 ± 9.96 years, with 38.5% being female. The mean HbA1C level was 7.2 ± 1.7%. Comorbidities included HBP in 88.1% of patients, with a mean SBP and DBP of 133.2 ± 13.7 mm Hg and 79.9 ± 9 mm Hg, respectively, and obesity in 66.41%, with a mean BMI of 33 ± 6.33 kg/m2. The mean LDL-C levels varied by CV risk category: 90.1 ± 34.22 mg/dL in very high risk, 98.63 ± 33.26 mg/dL in high risk, and 105 ± 37.1 mg/dL in moderate risk. Prescribed treatments included metformin (100%), statins (77.5%), GLP-1 Ras (29.4%), and SGLT-2is (29.4%). Conclusions: In Romania, patients with T2DM often achieve glycemic control targets but fail to meet composite targets that include glycemic, BP, and lipid control. Additionally, few patients benefit from innovative glucose-lowering therapies with proven cardio-renal benefits or from statins. Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) share a bidirectional link, and the innovative antidiabetic molecules GLP-1 Ras and SGLT-2is have proven cardiac and renal benefits, respectively. This study aimed to evaluate CV risk categories, along with lipid-lowering and antidiabetic treatments, in patients with T2DM from a real-life setting in Romania. A cross-sectional evaluation was conducted on 405 consecutively admitted patients with T2DM in an ambulatory setting, assessing them according to the 2019 ESC/EAS guidelines for moderate, high, and very high CV risk categories. The average age of the group was 58 ± 9.96 years, with 38.5% being female. The mean HbA1C level was 7.2 ± 1.7%. Comorbidities included HBP in 88.1% of patients, with a mean SBP and DBP of 133.2 ± 13.7 mm Hg and 79.9 ± 9 mm Hg, respectively, and obesity in 66.41%, with a mean BMI of 33 ± 6.33 kg/m . The mean LDL-C levels varied by CV risk category: 90.1 ± 34.22 mg/dL in very high risk, 98.63 ± 33.26 mg/dL in high risk, and 105 ± 37.1 mg/dL in moderate risk. Prescribed treatments included metformin (100%), statins (77.5%), GLP-1 Ras (29.4%), and SGLT-2is (29.4%). In Romania, patients with T2DM often achieve glycemic control targets but fail to meet composite targets that include glycemic, BP, and lipid control. Additionally, few patients benefit from innovative glucose-lowering therapies with proven cardio-renal benefits or from statins.
Audience	Academic
Author	Salmen, Teodor Pietrosel, Valeria-Anca Potcovaru, Claudia-Gabriela Bica, Ioana-Cristina Stoian, Anca Pantea Dumitriu-Stan, Roxana-Ioana Cimpeanu, Radu Cristian Iancu, Mihaela Adela Reurean-Pintilei, Delia Cretoiu, Sanda Maria Salmen, Bianca-Margareta Diaconu, Camelia-Cristina
AuthorAffiliation	2 DiabetMed Clinic, 052034 Bucharest, Romania 6 Doctoral School, University of Medicine and Pharmacy, 200349 Craiova, Romania 1 Doctoral School, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; teodor.salmen@drd.umfcd.ro (T.S.) 7 5th Department, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; camelia.diaconu@umfcd.ro 3 Department of Medical-Surgical and Complementary Sciences, Faculty of Medicine and Biological Sciences, “Ștefan cel Mare” University, 720229 Suceava, Romania; delia.pintilei@usm.ro 5 Department of Internal, Family and Occupational Medicine, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania 4 Department of Diabetes, Nutrition and Metabolic Diseases, Consulted Medical Centre, 700544 Iasi, Romania 9 Diabetes, Nutrition and Metabolic Diseases Department, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; anca.stoian@umfcd.ro 8 Department of Morphological Sciences, Cel
AuthorAffiliation_xml	– name: 3 Department of Medical-Surgical and Complementary Sciences, Faculty of Medicine and Biological Sciences, “Ștefan cel Mare” University, 720229 Suceava, Romania; delia.pintilei@usm.ro – name: 4 Department of Diabetes, Nutrition and Metabolic Diseases, Consulted Medical Centre, 700544 Iasi, Romania – name: 2 DiabetMed Clinic, 052034 Bucharest, Romania – name: 9 Diabetes, Nutrition and Metabolic Diseases Department, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; anca.stoian@umfcd.ro – name: 7 5th Department, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; camelia.diaconu@umfcd.ro – name: 5 Department of Internal, Family and Occupational Medicine, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania – name: 1 Doctoral School, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; teodor.salmen@drd.umfcd.ro (T.S.) – name: 8 Department of Morphological Sciences, Cell and Molecular Biology and Histology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; sanda.cretoiu@umfcd.ro – name: 6 Doctoral School, University of Medicine and Pharmacy, 200349 Craiova, Romania
Author_xml	– sequence: 1 givenname: Teodor orcidid: 0000-0003-4548-7441 surname: Salmen fullname: Salmen, Teodor – sequence: 2 givenname: Valeria-Anca surname: Pietrosel fullname: Pietrosel, Valeria-Anca – sequence: 3 givenname: Delia orcidid: 0000-0002-3116-8151 surname: Reurean-Pintilei fullname: Reurean-Pintilei, Delia – sequence: 4 givenname: Mihaela Adela orcidid: 0000-0003-2881-878X surname: Iancu fullname: Iancu, Mihaela Adela – sequence: 5 givenname: Radu Cristian surname: Cimpeanu fullname: Cimpeanu, Radu Cristian – sequence: 6 givenname: Ioana-Cristina orcidid: 0000-0002-8957-5980 surname: Bica fullname: Bica, Ioana-Cristina – sequence: 7 givenname: Roxana-Ioana orcidid: 0000-0003-4568-2714 surname: Dumitriu-Stan fullname: Dumitriu-Stan, Roxana-Ioana – sequence: 8 givenname: Claudia-Gabriela orcidid: 0009-0003-5801-5416 surname: Potcovaru fullname: Potcovaru, Claudia-Gabriela – sequence: 9 givenname: Bianca-Margareta orcidid: 0000-0002-8957-737X surname: Salmen fullname: Salmen, Bianca-Margareta – sequence: 10 givenname: Camelia-Cristina orcidid: 0000-0001-6837-260X surname: Diaconu fullname: Diaconu, Camelia-Cristina – sequence: 11 givenname: Sanda Maria orcidid: 0000-0003-2575-4880 surname: Cretoiu fullname: Cretoiu, Sanda Maria – sequence: 12 givenname: Anca Pantea orcidid: 0000-0003-0555-526X surname: Stoian fullname: Stoian, Anca Pantea
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/39338411$$D View this record in MEDLINE/PubMed
BookMark	eNptkl1r2zAUhs3oWD-2m_2AYdhNGaTTkWVbuhoh-yp0bIzsWijSUapgW5kkB_rvpyRd05TiCxmdR6_Oe_SeFyeDH7Ao3gK5qipBPq5voSUCKBMvijNglE04Ze3Jo__T4jzGFSF1CwxeFaeVqCrOAM6KzTRGjNENy3KmgnF-o6IeOxXKuQpLTOU0JeWGHodUuqGc362xpOVnpxaYMJY_sOtcGmP5SyWXmbiDMCSnwt0Bm-UShm3tt-_V4NTr4qVVXcQ39-tF8efrl_ns--Tm57fr2fRmomtG0qSugAqwjBsUCIJTCwqI1lgbyixii0gVawQy21iObfZryMJUnDZaNKauLorrva7xaiXXwfW5L-mVk7sNH5ZS5WZ1h5JaDdSwWlhLmWaKgxCspWhzDwvTiqz1aa-1Hhc9Gp09BdUdiR5XBncrl34jAVjFWoCscHmvEPzfEWOSvYs6j1AN6McoK4D8jkB4k9H3T9CVH8OQZ7WjmloI4AdqqbIDN1ifL9ZbUTnlQFrOGsIydfUMlT-DvdM5S9bl_aMD7x47fbD4PzYZ-LAHdPAxBrQPCBC5zaQ8ZDLD5AmsXcpx8dspue65I_8Ad1Lh8g
CitedBy_id	crossref_primary_10_3390_ph17101322 crossref_primary_10_1002_jcla_70029 crossref_primary_10_3390_biomedicines13092174 crossref_primary_10_1111_1440_1681_70021 crossref_primary_10_3390_medicina61030548 crossref_primary_10_3390_ijms26073081 crossref_primary_10_3390_biomedicines13061491 crossref_primary_10_3390_biomedicines13092306 crossref_primary_10_3390_jcm14103536
Cites_doi	10.4158/EP171764.APPGL 10.1007/s00508-016-1143-1 10.1111/1753-0407.12297 10.1161/CIR.0000000000001052 10.2337/dc24-S010 10.1016/S0895-7061(99)00252-6 10.3390/jcm12175563 10.1186/s12902-022-01026-2 10.1159/000511023 10.1016/j.diabres.2021.109119 10.1016/j.lanepe.2023.100624 10.1038/s41371-020-00417-z 10.3390/life13030839 10.21037/gs.2019.12.03 10.1016/j.atherosclerosis.2021.08.035 10.3390/jcm13051252 10.1093/eurheartj/ehab484 10.1186/s40798-015-0031-y 10.1016/S2213-8587(19)30388-2 10.1097/01.hjh.0000748880.95364.6c 10.1186/s12933-020-01164-8 10.1111/dme.13825 10.1016/j.numecd.2017.04.009 10.1159/000525792 10.1016/j.diabres.2020.108535 10.3390/jcm12123925 10.1093/eurheartj/ehad192 10.3390/jcm13082196 10.3390/biomedicines10102624 10.1097/XCE.0000000000000135 10.1016/j.diabres.2018.06.008 10.1016/S1734-1140(13)71054-5 10.2991/jegh.k.191028.001 10.1080/14779072.2023.2192926 10.1016/j.pcad.2019.08.003 10.1016/j.jdiacomp.2022.108389 10.2337/dc23-S009 10.1093/eurheartj/ehz455 10.1186/s12933-023-01875-8 10.1016/j.jacc.2018.11.003
ContentType	Journal Article
Copyright	COPYRIGHT 2024 MDPI AG 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2024 by the authors. 2024
Copyright_xml	– notice: COPYRIGHT 2024 MDPI AG – notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2024 by the authors. 2024
DBID	AAYXX CITATION NPM 3V. 7XB 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO GNUQQ GUQSH M2O MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA
DOI	10.3390/ph17091249
DatabaseName	CrossRef PubMed ProQuest Central (Corporate) ProQuest Central (purchase pre-March 2016) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central ProQuest Central Student ProQuest Research Library Research Library Research Library (Corporate) ProQuest Databases ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Basic ProQuest Central Essentials ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest One Academic UKI Edition ProQuest Central Korea ProQuest Research Library ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic Publicly Available Content Database PubMed CrossRef
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology
EISSN	1424-8247
ExternalDocumentID	oai_doaj_org_article_2fc12d459ff24c4a8199472ef312bd79 PMC11434711 A810784604 39338411 10_3390_ph17091249
Genre	Journal Article
GeographicLocations	Romania
GeographicLocations_xml	– name: Romania
GroupedDBID	--- 2WC 53G 5VS 8G5 AADQD AAFWJ AAYXX ABDBF ABUWG ACGFO ACIHN ACUHS ADBBV AEAQA AFFHD AFKRA AFPKN AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ CCPQU CITATION DIK DWQXO EBD ESX GNUQQ GROUPED_DOAJ GUQSH GX1 HH5 HYE IAO IHR ITC KQ8 M2O M48 MK0 MODMG M~E OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RPM TUS NPM 3V. 7XB 8FK COVID MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c540t-531291f48de9e1982f1a10cce5d24fee7ee2a469e4f6f8e7424d0bd3826c96d53
IEDL.DBID	DOA
ISICitedReferencesCount	9
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001323514900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1424-8247
IngestDate	Fri Oct 03 12:51:14 EDT 2025 Tue Nov 04 02:05:38 EST 2025 Thu Oct 02 04:12:05 EDT 2025 Mon Jun 30 16:02:21 EDT 2025 Sat Nov 29 13:54:52 EST 2025 Sat Nov 29 10:32:12 EST 2025 Mon Jul 21 05:40:19 EDT 2025 Tue Nov 18 21:44:51 EST 2025 Sat Nov 29 07:12:05 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9
Keywords	LDL-cholesterol cardiovascular disease statin type 2 diabetes mellitus risk cardio-renal protection sodium-glucose co-transporter-2 inhibitors glucagon-like peptide-1 receptor agonists
Language	English
License	Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c540t-531291f48de9e1982f1a10cce5d24fee7ee2a469e4f6f8e7424d0bd3826c96d53
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0003-2881-878X 0000-0002-8957-5980 0000-0003-4568-2714 0000-0002-8957-737X 0000-0001-6837-260X 0000-0003-0555-526X 0000-0002-3116-8151 0009-0003-5801-5416 0000-0003-4548-7441 0000-0003-2575-4880
OpenAccessLink	https://doaj.org/article/2fc12d459ff24c4a8199472ef312bd79
PMID	39338411
PQID	3110659918
PQPubID	2032350
ParticipantIDs	doaj_primary_oai_doaj_org_article_2fc12d459ff24c4a8199472ef312bd79 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11434711 proquest_miscellaneous_3110911086 proquest_journals_3110659918 gale_infotracmisc_A810784604 gale_infotracacademiconefile_A810784604 pubmed_primary_39338411 crossref_primary_10_3390_ph17091249 crossref_citationtrail_10_3390_ph17091249
PublicationCentury	2000
PublicationDate	2024-09-01
PublicationDateYYYYMMDD	2024-09-01
PublicationDate_xml	– month: 09 year: 2024 text: 2024-09-01 day: 01
PublicationDecade	2020
PublicationPlace	Switzerland
PublicationPlace_xml	– name: Switzerland – name: Basel
PublicationTitle	Pharmaceuticals (Basel, Switzerland)
PublicationTitleAlternate	Pharmaceuticals (Basel)
PublicationYear	2024
Publisher	MDPI AG MDPI
Publisher_xml	– name: MDPI AG – name: MDPI
References	Vencio (ref_39) 2020; 63 Stival (ref_29) 2022; 15 Shariq (ref_31) 2020; 9 Scheen (ref_8) 2018; 143 ref_13 Ginsberg (ref_43) 2022; 42 Arca (ref_44) 2022; 109 Khan (ref_3) 2020; 10 Kannel (ref_25) 2000; 13 Huang (ref_12) 2015; 1 Visseren (ref_24) 2021; 42 Cokolic (ref_27) 2017; 129 Alonso (ref_45) 2023; 21 Manolescu (ref_11) 2013; 65 ref_18 Rungby (ref_33) 2017; 6 Grundy (ref_38) 2019; 73 ref_17 Wang (ref_21) 2020; 8 Pop (ref_30) 2021; 35 ElSayed (ref_14) 2024; 47 Acharya (ref_9) 2019; 62 Mota (ref_4) 2016; 8 Jellinger (ref_37) 2017; 23 Vrablik (ref_35) 2021; 334 Handelsman (ref_19) 2023; 37 Marx (ref_20) 2023; 44 ref_23 Sun (ref_1) 2022; 183 McGurnaghan (ref_32) 2019; 36 ref_42 Mach (ref_15) 2020; 41 Ray (ref_34) 2023; 29 ref_40 Chen (ref_22) 2023; 22 ref_2 Tsao (ref_16) 2022; 145 Vintila (ref_26) 2021; 39 Janssen (ref_28) 2020; 13 Nesti (ref_10) 2017; 27 Banach (ref_41) 2021; 172 ElSayed (ref_5) 2023; 46 ref_7 ref_6 Morieri (ref_36) 2020; 19
References_xml	– volume: 23 start-page: 1 year: 2017 ident: ref_37 article-title: American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease publication-title: Endocr. Pract. doi: 10.4158/EP171764.APPGL – volume: 129 start-page: 192 year: 2017 ident: ref_27 article-title: Patterns of diabetes care in Slovenia, Croatia, Serbia, Bulgaria and Romania: An observational, non-interventional, cross-sectional study publication-title: Wien. Klin. Wochenschr. doi: 10.1007/s00508-016-1143-1 – volume: 8 start-page: 336 year: 2016 ident: ref_4 article-title: Prevalence of diabetes mellitus and prediabetes in the adult Romanian population: PREDATORR study publication-title: J. Diabetes doi: 10.1111/1753-0407.12297 – volume: 145 start-page: e153 year: 2022 ident: ref_16 article-title: Heart disease and stroke statistics—2022 update: A report from the American Heart Association publication-title: Circulation doi: 10.1161/CIR.0000000000001052 – volume: 47 start-page: 179 year: 2024 ident: ref_14 article-title: 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024 publication-title: Diabetes Care doi: 10.2337/dc24-S010 – volume: 13 start-page: 3S year: 2000 ident: ref_25 article-title: Risk stratification in hypertension: New insights from the Framingham Study publication-title: Am. J. Hypertens. doi: 10.1016/S0895-7061(99)00252-6 – ident: ref_42 doi: 10.3390/jcm12175563 – ident: ref_40 doi: 10.1186/s12902-022-01026-2 – volume: 42 start-page: e48 year: 2022 ident: ref_43 article-title: Lipoprotein (a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American Heart Association publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 13 start-page: 514 year: 2020 ident: ref_28 article-title: Obesity prevalence in the long-term future in 18 European countries and in the USA publication-title: Obes. Facts doi: 10.1159/000511023 – volume: 109 start-page: 18 year: 2022 ident: ref_44 article-title: Lipoprotein(a): A risk factor for atherosclerosis and an emerging therapeutic target publication-title: Heart – volume: 183 start-page: 109119 year: 2022 ident: ref_1 article-title: IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 publication-title: Diabetes Res. Clin. Pract. doi: 10.1016/j.diabres.2021.109119 – volume: 29 start-page: 100624 year: 2023 ident: ref_34 article-title: Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: The multinational observational SANTORINI study publication-title: Lancet Reg. Health Eur. doi: 10.1016/j.lanepe.2023.100624 – volume: 35 start-page: 884 year: 2021 ident: ref_30 article-title: High-normal blood pressure and related cardiovascular risk factors prevalence in the Romanian adult population: Insights from the SEPHAR III study publication-title: J. Hum. Hypertens. doi: 10.1038/s41371-020-00417-z – ident: ref_7 doi: 10.3390/life13030839 – volume: 9 start-page: 80 year: 2020 ident: ref_31 article-title: Obesity-related hypertension: A review of pathophysiology, management, and the role of metabolic surgery publication-title: Gland. Surg. doi: 10.21037/gs.2019.12.03 – volume: 334 start-page: 66 year: 2021 ident: ref_35 article-title: Lipid-lowering therapy use in Central and Eastern Europe primary and secondary care: DA VINCI observational study publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2021.08.035 – ident: ref_13 doi: 10.3390/jcm13051252 – ident: ref_18 – volume: 42 start-page: 3227 year: 2021 ident: ref_24 article-title: 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehab484 – volume: 1 start-page: 32 year: 2015 ident: ref_12 article-title: Obesity-Related Oxidative Stress: The Impact of Physical Activity and Diet Manipulation publication-title: Sports Med.-Open doi: 10.1186/s40798-015-0031-y – volume: 8 start-page: 36 year: 2020 ident: ref_21 article-title: Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: A systematic review and meta-analysis of randomised trials including 327,037 participants publication-title: Lancet Diabetes Endocrinol. doi: 10.1016/S2213-8587(19)30388-2 – volume: 39 start-page: e375 year: 2021 ident: ref_26 article-title: Target Achievement in Very High Risk Patients in Light of the New Dyslipidemia Guidelines publication-title: J. Hypertens. doi: 10.1097/01.hjh.0000748880.95364.6c – volume: 19 start-page: 190 year: 2020 ident: ref_36 article-title: Cholesterol-lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: Unmet needs in a large population of outpatients at specialist clinics publication-title: Cardiovasc. Diabetol. doi: 10.1186/s12933-020-01164-8 – volume: 36 start-page: 718 year: 2019 ident: ref_32 article-title: Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: A contemporary analysis publication-title: Diabet. Med. doi: 10.1111/dme.13825 – volume: 27 start-page: 657 year: 2017 ident: ref_10 article-title: Metformin Effects on the Heart and the Cardiovascular System: A Review of Experimental and Clinical Data publication-title: Nutr. Metab. Cardiovasc. Dis. doi: 10.1016/j.numecd.2017.04.009 – volume: 15 start-page: 655 year: 2022 ident: ref_29 article-title: Prevalence and Correlates of Overweight and Obesity in 12 European Countries in 2017–2018 publication-title: Obes. Facts doi: 10.1159/000525792 – volume: 172 start-page: 108535 year: 2021 ident: ref_41 article-title: Cardio-Metabolic Academy Europe East. Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel publication-title: Diabetes Res. Clin. Pract. doi: 10.1016/j.diabres.2020.108535 – volume: 63 start-page: A945 year: 2020 ident: ref_39 article-title: Contemporary use of diabetes medications with a cardiovascular indication in adults with type 2 diabetes: A secondary analysis of the multinational CAPTURE study publication-title: Diabetologia – ident: ref_6 doi: 10.3390/jcm12123925 – volume: 44 start-page: 4043 year: 2023 ident: ref_20 article-title: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehad192 – ident: ref_23 doi: 10.3390/jcm13082196 – ident: ref_2 doi: 10.3390/biomedicines10102624 – volume: 6 start-page: 145 year: 2017 ident: ref_33 article-title: Prevalence of cardiovascular disease and evaluation of standard of care in type 2 diabetes: A nationwide study in primary care publication-title: Cardiovasc. Endocrinol. doi: 10.1097/XCE.0000000000000135 – volume: 143 start-page: 88 year: 2018 ident: ref_8 article-title: Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists publication-title: Diabetes Res. Clin. Pract. doi: 10.1016/j.diabres.2018.06.008 – volume: 65 start-page: 743 year: 2013 ident: ref_11 article-title: Effect of the Nutritional Supplement ALAnerv® on the Serum PON1 Activity in Post-Acute Stroke Patients publication-title: Pharmacol. Rep. doi: 10.1016/S1734-1140(13)71054-5 – volume: 10 start-page: 107 year: 2020 ident: ref_3 article-title: Epidemiology of Type 2 Diabetes—Global Burden of Disease and Forecasted Trends publication-title: J. Epidemiol. Glob. Health doi: 10.2991/jegh.k.191028.001 – volume: 21 start-page: 241 year: 2023 ident: ref_45 article-title: What are the controversies and appropriate guidance for cascade screening for lipoprotein (a)? publication-title: Expert. Rev. Cardiovasc. Ther. doi: 10.1080/14779072.2023.2192926 – ident: ref_17 – volume: 62 start-page: 342 year: 2019 ident: ref_9 article-title: Cardiovascular outcome trials of the newer anti-diabetic medications publication-title: Prog. Cardiovasc. Dis. doi: 10.1016/j.pcad.2019.08.003 – volume: 37 start-page: 108389 year: 2023 ident: ref_19 article-title: Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases publication-title: J. Diabetes Complicat. doi: 10.1016/j.jdiacomp.2022.108389 – volume: 46 start-page: S140 year: 2023 ident: ref_5 article-title: 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes—2023 publication-title: Diabetes Care doi: 10.2337/dc23-S009 – volume: 41 start-page: 111 year: 2020 ident: ref_15 article-title: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehz455 – volume: 22 start-page: 146 year: 2023 ident: ref_22 article-title: Intensified glycemic control by HbA1c for patients with coronary heart disease and type 2 diabetes: A review of findings and conclusions publication-title: Cardiovasc. Diabetol. doi: 10.1186/s12933-023-01875-8 – volume: 73 start-page: e285 year: 2019 ident: ref_38 article-title: 2018 guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2018.11.003
SSID	ssj0057141
Score	2.3948581
Snippet	Introduction: Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) share a bidirectional link, and the innovative antidiabetic molecules GLP-1 Ras... Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) share a bidirectional link, and the innovative antidiabetic molecules GLP-1 Ras and SGLT-2is...
SourceID	doaj pubmedcentral proquest gale pubmed crossref
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source
StartPage	1249
SubjectTerms	Antidiabetics Atherosclerosis cardio-renal protection cardiovascular disease Cardiovascular diseases Care and treatment Complications and side effects Demographic aspects Diabetes Diabetic neuropathy Diagnosis Disease Exercise Fatalities Glucose LDL-cholesterol Lipids Metabolic disorders Mortality Oxidative stress Patients risk Risk factors statin Statins Type 2 diabetes type 2 diabetes mellitus Weight control
SummonAdditionalLinks	– databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZgy4FLeUOgICNQEVKjrh3ndULbqhUHWK2qReotcvygK6Fkm2Qr7b9nJnE2G4G4cI0nkS2PZ-ZzPn8m5GMoTKo4j32V5sYXAAj8XCahH8o8Co2dSqZbndlv8XyeXF-nC7fhVjtaZR8T20CtS4V75KcB5KkohGom-bK-9fHWKPy76q7QuE8OUKlMTMjB2cV8cdXH4jBmgnWipAGA-9P1DYshQXJUztxLQ61a_58xeS8pjQmTexno8tH_9v0xOXS1J511zvKE3DPFU3K86MSrtyd0OZzFqk_oMV0MstbbZ-Su-z8MqY6ej0isdNmyyems6ckFdFVQBLiUU8e4qel3VP5sNjVddEqudWuErG5ZbQcz3G02FbZdlSjNIZ-TH5cXy_Ovvru1wVdQ_TU-LGqeMisSbVLD0oRbJtlUKRNqLqwxsTFcAig3wkY2MQDNhZ7mOgCco9JIh8ELMinKwrwiNLA5xEAbQYmmhRZcRrFB3o40WAbFoUc-95OYKSdpjjdr_MoA2uCEZ8OEe-TDznbdCXn81eoMfWFngeLb7YOy-pm5tZxxqxjXIkyt5UIJmaC-csyNhZHnOoaPfEJPyjBEQHeUdCcdYFAotpXNEsDcUPdNhUeORpawtNW4ufenzIWWOhucySPvd834JtLlClNuOpsUD3hEHnnZue5uSEEaBIlgzCPJyKlHYx63FKubVngcsHMAxQx7_e9-vSEPOZR-HRPviEyaamPekgfqrlnV1Tu3RH8DRfRHzA priority: 102 providerName: ProQuest
Title	Assessing Cardiovascular Target Attainment in Type 2 Diabetes Mellitus Patients in Tertiary Diabetes Center in Romania
URI	https://www.ncbi.nlm.nih.gov/pubmed/39338411 https://www.proquest.com/docview/3110659918 https://www.proquest.com/docview/3110911086 https://pubmed.ncbi.nlm.nih.gov/PMC11434711 https://doaj.org/article/2fc12d459ff24c4a8199472ef312bd79
Volume	17
WOSCitedRecordID	wos001323514900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1424-8247 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057141 issn: 1424-8247 databaseCode: DOA dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1424-8247 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057141 issn: 1424-8247 databaseCode: M~E dateStart: 20040101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1424-8247 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057141 issn: 1424-8247 databaseCode: BENPR dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1424-8247 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057141 issn: 1424-8247 databaseCode: PIMPY dateStart: 20040101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1424-8247 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057141 issn: 1424-8247 databaseCode: M2O dateStart: 20040101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Ni9swEB3abQ-9lH7X7TaotGwprNlIlm35mF12aaFJzZJCejKyLLGB4ixxspB_3xnL-TAt9NKLD9YYLGukeS95egL4GEubGSHS0GSlDSUSgrDUKg5jXSaxdUPNq9Zn9ls6majZLMsPjvoiTZi3B_Yf7kw4w0Ul48w5IY3UisxsU2FdxEVZpe3WPUQ9WzLl1-A45ZJ7M9IISf3Z7Q1PsTAKcsw8KD-tS_-fa_FBMeoLJQ8qz9UTeNxBRjbyr_oU7tn6GZzk3nN6c8qm-y1UzSk7YfnejXrzHO7837pYodhFT3vKpq0InI1WW00Am9eMeCkTrBPKNGxMhp2rdcNyb8DatEEkxtbLzT6MfiS2S2q7XpCjhn4BP64upxdfwu6whdAgaFuFOBdFxp1Ulc0sz5RwXPOhMTauhHTWptYKjVzaSpc4ZZFRy2pYVhHSE5MlVRy9hKN6UdvXwCJX4tLlEkRWlayk0ElqSW6jLaGXNA7g83YMCtM5kdOBGL8KZCQ0XsV-vAL4sIu99f4bf406p6HcRZBndnsDM6noMqn4VyYF8IkSoaCZja9jdLdBATtFHlnFSCFVRrg2lAEc9yJxRpp-8zaVim5FaIoIcVYSIxpXAbzfNdOTpHKr7WLtYzLal5EE8Mpn3q5LURZFSnIegOrlZK_P_ZZ6ftP6hSPljRCD8Df_4yu9hUcCcZ2X2R3D0Wq5tu_goblbzZvlAO6nMzWAB-eXk_x60M5JvI7Fd7yXfx3nP38DJFU9Ug
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF5VBQkuvB-GAouAIqRa9a7XrwNCoVC1ahoiFKTezHofNBKyg50U5U_xG5nxI4kF4tYDV-_Y8tqz38zY335DyMtAmERxHrkqyYwroCBwMxkHbiCzMDDWk0zXOrPDaDSKz86S8Rb51e2FQVplh4k1UOtC4TfyfR_iVBhANhO_m_1wsWsU_l3tWmg0bnFilj-hZKveHn-A9_uK88OPk4Mjt-0q4CrITuYuOB1PmBWxNomBkptbJpmnlAk0F9aYyBguoWg0woY2NlA6Cu1l2oc8XCWhxi4RAPlXBCqLIVWQf-qQP4iYYI0Equ8n3v7snEUQjjnqdG4Evbo3wJ8RYCME9umZG_Hu8Ob_9qRukRttZk0HzVK4TbZMfofsjhtp7uUenax3mlV7dJeO16Ldy7vkovn7DYGcHvQounRSc-XpYN5RJ-g0p1i-U05bPlFFT1HXdL6o6LjRqa1qI-Ssy3K5NsNv6abEsc8FCo_Ie-TLpTyT-2Q7L3LzkFDfZoDwNoQEVAstuAwjg6wkaTDJiwKHvOmcJlWtYDv2DfmeQuGGDpauHcwhL1a2s0am5K9W79H3VhYoLV4fKMpvaYtUKbeKcS2CxFoulJAxqkdH3FiYeaYjuMhr9NwUARBuR8l2HwdMCqXE0kHMIO0UoSccstOzBOBS_eHOf9MWOKt07bwOeb4axjORDJibYtHYJLh9JXTIg2aprKbkJ74fC8YcEvcWUW_O_ZF8el7LqjMoHSBVY4_-fV_PyLWjyekwHR6PTh6T6xyS3IZzuEO25-XCPCFX1cV8WpVPa3Cg5Otlr7Hf2uuj3g
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF5VBSEu5Q2GAouAIqRaya7XrwNCoSWiagkRSqXezHofbSRkBzspyl_j1zHjRxILxK0HrtlJ5HVm5puxv_2GkFe-MLHiPHRVnBpXQEPgpjLyXV-mgW9sXzJd6cyehKNRdHYWj7fIr_YsDNIq25xYJWqdK3xG3vMApwIfqpmoZxtaxPhw-H72w8UJUvimtR2nUbvIsVn-hPatfHd0CP_1a86HHycHn9xmwoCroFKZu-CAPGZWRNrEBtpvbplkfaWMr7mwxoTGcAkNpBE2sJGBNlLofqo9qMlVHGicGAHp_1ooAJSRNsi_tCjgh0ywWg7V8-J-b3bBQoBmjpqdGwBYzQn4Ew024LBL1dzAvuGt__mu3SY7TcVNB3WI3CFbJrtL9sa1ZPdyn07WJ9DKfbpHx2sx7-U9clm_FQeApwcd6i6dVBx6Opi3lAo6zSi29ZTThmdU0s-odzpflHRc69eWlRFy2WWxXJvhM3ZT4NrXHAVJ5H1yeiX35AHZzvLMPCLUsylkfhtAYaqFFlwGoUG2kjRY_IW-Q962DpSoRsgd54l8T6ChQ2dL1s7mkJcr21ktX_JXqw_ohysLlByvPsiL86TJYAm3inEt_NhaLpSQEapKh9xY2HmqQ_iRN-jFCSZGuBwlm_MdsCmUGEsGEYNyVAR94ZDdjiUkNNVdbn05aRJqmawd2SEvVsv4TSQJZiZf1DYxHmsJHPKwDpvVlrzY8yLBmEOiTkB19txdyaYXldw6g5YCSjj2-N_X9ZzcgNBKTo5Gx0_ITQ61b01F3CXb82JhnpLr6nI-LYtnVZ6g5NtVh9hvEeespA
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Assessing+Cardiovascular+Target+Attainment+in+Type+2+Diabetes+Mellitus+Patients+in+Tertiary+Diabetes+Center+in+Romania&rft.jtitle=Pharmaceuticals+%28Basel%2C+Switzerland%29&rft.au=Salmen%2C+Teodor&rft.au=Pietrosel%2C+Valeria-Anca&rft.au=Reurean-Pintilei%2C+Delia&rft.au=Iancu%2C+Mihaela+Adela&rft.date=2024-09-01&rft.issn=1424-8247&rft.eissn=1424-8247&rft.volume=17&rft.issue=9&rft.spage=1249&rft_id=info:doi/10.3390%2Fph17091249&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_ph17091249
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1424-8247&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1424-8247&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1424-8247&client=summon